Starting 2025 with the publication of some of our best engineering, our bacterial delivery vector for clinical use. This paper is the culmination of years of testing, developing and learning how to overcome some of the challenges in bacterial therapies. Using this technology, we are creating a whole new and safe way of delivering drugs to solid tumors more specifically and more efficiently. Our focus remains on creating new therapies for advanced tumors with few to no treatment options. https://lnkd.in/eKqCyQUc
关于我们
Ernest Pharmaceuticals LLC was founded in 2016 by Dr. Neil Forbes and Dr. Nele Van Dessel at the University of Massachusetts at Amherst. Ernest Pharmaceuticals seeks to create a novel bacterial platform that revolutionizes cancer treatment success through innovations in intracellular macromolecule delivery.
- 网站
-
https://www.ernestpharma.com
Ernest Pharmaceuticals的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- HADLEY，MA
- 类型
- 私人持股
地点
-
主要
获取路线
2 Ladyslipper lane
US，MA，HADLEY，01035
Ernest Pharmaceuticals员工
-
John Ketchum
Senior Business Advisor at Bonnieview Consulting, LLC
-
Neil Forbes
Professor at University of Massachusetts
-
Nele Van Dessel
CEO at Ernest Pharmaceuticals Inc / Termeer Fellow
-
Vishnu Raman, PhD
Therapeutic Development | Synthetic Biology | Immunology | Cancer Biology | Infectious Disease
动态
-
The versatility of bacteria is never-ending. In collaboration with the Forbes Lab, our BacID vectors were able to deliver the DNA of oncolytic viruses(OV) directly into cancer cells, resulting in the production of active, viral particles in tumor cells. Producing oncolytic virus directly in tumor cells can overcome some of the obstacles seen with IV administration of OV's. Shoutout to Shradha Khanduja, the highly talented and tenacious engineer behind this work! https://lnkd.in/dAuxHZ39